Compare Inovio Pharmaceuticals Inc (INO) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Snowflake Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Snowflake Inc trades at $272 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 1065.2× Inovio Pharmaceuticals Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SNOW | |
|---|---|---|
Market Cap | $89.27M | $95.09B |
Sector | Health | Technology |
52-Week High | $2.87 | $280.16 |
52-Week Low | $1.05 | $121.11 |
Enterprise Value | $60.28M | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Snowflake (SNOW) trades at $271.73, up 1.05% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth from $1.2B in 2022 to $3.63B in 2025, though profitability remains negative with a -23.79% net margin. Analyst sentiment is overwhelmingly positive with 80.77% buy ratings and a $299.91 consensus target, while recent news highlights AI Data Cloud expansion and enterprise adoption.
Snowflake presents a growth investment opportunity with accelerating AI platform adoption and 30% revenue targets, but faces execution risks in achieving profitability amid high valuation multiples. The stock's upside depends on converting revenue growth to positive earnings while navigating competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
